Objective:To investigate whether malignant tumors affect the laboratory outcomes of patients in their first controlled ovarian hyperstimulation (COH) cycle.Methods:This study was a retrospective case-control study that analyzed the clinical and laboratory data of patients who underwent fertility preservation before chemotherapy and radiotherapy due to malignant tumors, as well as patients with infertility caused by tubal factors who first underwent in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University from January 2020 to May 2024. Patients who underwent fertility preservation were designated as the research group, while patients who underwent assisted reproduction due to tubal factors during the same period were designated as control group. After 1∶3 propensity score matching (PSM), 40 patients were included in the research group and 118 patients were included in control group. The ovarian response, oocyte retrieval outcomes, and embryonic development after fertilization in the first COH cycle were compared between the two groups. Results:After PSM, the research group and control group showed statistically significant differences in the gonadotropin (Gn) starting dosage [225.00 (162.50, 300.00) U vs. 193.75 (150.00, 225.00) U, P=0.002], duration of Gn used [10.00 (8.00, 11.00) d vs. 12.00 (10.00, 13.00) d, P<0.001], and average estradiol levels on human chorionic gonadotropin trigger day [2 487.00 (1 461.25, 4 090.25) pmol/L vs. 10 738.50 (8 400.00, 16 507.25) pmol/L, P<0.001]. However, no statistically significant difference was found in the total dosages of Gn used between the two groups ( P>0.05). There were no significant differences between the groups in terms of the number of oocytes retrieved, the number of metaphase Ⅱ oocytes, two pronuclei (2PN) rate, 2PN cleavage rate, available embryo rate, high-quality embryo rate, blastocyst formation rate, and available blastocyst formation rate (all P>0.05). Conclusion:Compared with infertility patients with tubal factors, there is no significant difference in the laboratory outcomes of malignant tumor patients undergoing COH for fertility preservation prior to chemotherapy and radiation.

Objective:To investigate the effects of male body mass index (BMI) on semen parameters and perinatal outcomes following artificial insemination by husband (AIH) treatment.Methods:A retrospective cohort study was conducted to analyze the clinical data of 5 053 patients underwent AIH treatment at the Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University, from January 2017 to February 2024. The study focused on factors such as male semen parameter abnormalities, male sexual dysfunction, female cervical factors, reproductive tract malformations, and unexplained infertility. Patients were classified into three groups based on male BMI: normal weight group (18.5-23.9 kg/m2, n=1 673), overweight group (24.0-27.9 kg/m2, n=2 078), and obese group (BMI≥28.0 kg/m2, n=1 302). The primary objective was to assess the differences in semen parameters and perinatal outcomes among the three groups. Multivariable logistic regression and linear regression analyses were applied to adjust for potential confounders that could influence semen parameters and perinatal outcomes. Results:Semen volume in the normal weight group and overweight group [4.00 (3.00, 5.50) mL, 4.00 (3.00, 5.50) mL] was higher than that in the obese group [4.00 (3.00, 5.00) mL], with a significant difference among the three groups ( P<0.001, a P<0.001). The total sperm count in the normal group and overweight group [207.60 (121.90, 341.75)×10 6, 211.80 (119.88, 334.83)×10 6] was higher than that in the obese group [188.40 (110.96, 323.41)×10 6], with a significant difference among the three groups ( P=0.007, a P<0.001). The total progressive sperm motility count in the normal group [88.18 (43.63, 163.80)×10 6] was higher than that in the obese group [75.30 (40.29, 147.86)×10 6], with a significant difference among the three groups ( P=0.001, a P<0.001). The percentage of forward motile sperm in the normal group [(45.37±17.16)%] was higher than that in the overweight group [(44.03±17.36)%] and the obese group [(43.80±17.21)%], with a significant difference compared among the three groups ( P=0.020, a P=0.016]. In terms of perinatal outcomes, after multivariate logistic regression analysis, only the overweight and obese groups had higher newborn birth weights [(3 389.53±472.65) g, (3 408.57±507.90) g] compared with the normal group [(3 271.32±532.02) g], with a significant difference among the three groups ( P=0.010, a P=0.009). Conclusion:Higher male BMI is associated with decreased semen quality and may increase newborn birth weight following AIH treatment.

Objective:To investigate whether malignant tumors affect the laboratory outcomes of patients in their first controlled ovarian hyperstimulation (COH) cycle.Methods:This study was a retrospective case-control study that analyzed the clinical and laboratory data of patients who underwent fertility preservation before chemotherapy and radiotherapy due to malignant tumors, as well as patients with infertility caused by tubal factors who first underwent in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) at the Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University from January 2020 to May 2024. Patients who underwent fertility preservation were designated as the research group, while patients who underwent assisted reproduction due to tubal factors during the same period were designated as control group. After 1∶3 propensity score matching (PSM), 40 patients were included in the research group and 118 patients were included in control group. The ovarian response, oocyte retrieval outcomes, and embryonic development after fertilization in the first COH cycle were compared between the two groups. Results:After PSM, the research group and control group showed statistically significant differences in the gonadotropin (Gn) starting dosage [225.00 (162.50, 300.00) U vs. 193.75 (150.00, 225.00) U, P=0.002], duration of Gn used [10.00 (8.00, 11.00) d vs. 12.00 (10.00, 13.00) d, P<0.001], and average estradiol levels on human chorionic gonadotropin trigger day [2 487.00 (1 461.25, 4 090.25) pmol/L vs. 10 738.50 (8 400.00, 16 507.25) pmol/L, P<0.001]. However, no statistically significant difference was found in the total dosages of Gn used between the two groups ( P>0.05). There were no significant differences between the groups in terms of the number of oocytes retrieved, the number of metaphase Ⅱ oocytes, two pronuclei (2PN) rate, 2PN cleavage rate, available embryo rate, high-quality embryo rate, blastocyst formation rate, and available blastocyst formation rate (all P>0.05). Conclusion:Compared with infertility patients with tubal factors, there is no significant difference in the laboratory outcomes of malignant tumor patients undergoing COH for fertility preservation prior to chemotherapy and radiation.

Objective:To investigate the effects of male body mass index (BMI) on semen parameters and perinatal outcomes following artificial insemination by husband (AIH) treatment.Methods:A retrospective cohort study was conducted to analyze the clinical data of 5 053 patients underwent AIH treatment at the Reproductive Health Hospital of the Third Affiliated Hospital of Zhengzhou University, from January 2017 to February 2024. The study focused on factors such as male semen parameter abnormalities, male sexual dysfunction, female cervical factors, reproductive tract malformations, and unexplained infertility. Patients were classified into three groups based on male BMI: normal weight group (18.5-23.9 kg/m2, n=1 673), overweight group (24.0-27.9 kg/m2, n=2 078), and obese group (BMI≥28.0 kg/m2, n=1 302). The primary objective was to assess the differences in semen parameters and perinatal outcomes among the three groups. Multivariable logistic regression and linear regression analyses were applied to adjust for potential confounders that could influence semen parameters and perinatal outcomes. Results:Semen volume in the normal weight group and overweight group [4.00 (3.00, 5.50) mL, 4.00 (3.00, 5.50) mL] was higher than that in the obese group [4.00 (3.00, 5.00) mL], with a significant difference among the three groups ( P<0.001, a P<0.001). The total sperm count in the normal group and overweight group [207.60 (121.90, 341.75)×10 6, 211.80 (119.88, 334.83)×10 6] was higher than that in the obese group [188.40 (110.96, 323.41)×10 6], with a significant difference among the three groups ( P=0.007, a P<0.001). The total progressive sperm motility count in the normal group [88.18 (43.63, 163.80)×10 6] was higher than that in the obese group [75.30 (40.29, 147.86)×10 6], with a significant difference among the three groups ( P=0.001, a P<0.001). The percentage of forward motile sperm in the normal group [(45.37±17.16)%] was higher than that in the overweight group [(44.03±17.36)%] and the obese group [(43.80±17.21)%], with a significant difference compared among the three groups ( P=0.020, a P=0.016]. In terms of perinatal outcomes, after multivariate logistic regression analysis, only the overweight and obese groups had higher newborn birth weights [(3 389.53±472.65) g, (3 408.57±507.90) g] compared with the normal group [(3 271.32±532.02) g], with a significant difference among the three groups ( P=0.010, a P=0.009). Conclusion:Higher male BMI is associated with decreased semen quality and may increase newborn birth weight following AIH treatment.

Objective:Analyzing the influence of morphological evaluation parameters of blastocysts, including days of blastocyst development [day 5 (D5) and day 6 (D6)], degree of blastocyst expansion (4, 5, 6), inner cell mass and trophectoderm grade, on the occurrence of chromosomal karyotype abnormalities of chorionic villi in missed abortion after in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment and fresh/frozen-thawed single blastocyst transfer. Methods:The clinical data of patients with missed abortion after IVF/ICSI treatment and fresh/frozen-thawed single blastocyst transfer from February 2015 to February 2023 in the Reproductive Center of the Third Affiliated Hospital of Zhengzhou University were included. Using a case-control study, the data were divided into two groups according to the detection results of chromosomal copy number variations (CNVs) in chorionic villi of missed abortion abnormal karyotype group ( n=139) and normal karyotype group ( n=82). The baseline data between the two groups were compared. Univariate logistic regression was used to investigate the effect of blastocyst morphological rating parameters on the occurrence of chromosomal karyotype abnormalities of chorionic villi in aborted tissues, and multivariate logistic regression was also used to adjust confounding factors. Results:Male age [(34.12±6.49) years], sperm morphology rate [5.00 (4.00,6.00)%] and female age [33.00 (30.00, 37.00) years] in abnormal karyotype group were higher than those in the normal karyotype group [(32.38±4.69) years, 4.00 (2.00,5.00)% and 31.50 (29.00,34.00) years], and the differences were statistically significant ( P=0.022, P=0.020, P=0.009). Univariate and multivariate logistic regression analyses showed that days of blastocyst development, degree of blastocyst expansion, inner cell mass and trophectoderm grade did not increase the risk of chromosomal karyotype abnormalities of chorionic villi (all P>0.05). Conclusion:There is no significant correlation between blastocyst morphological evaluation parameters and chromosomal karyotype abnormalities in chorionic villi of missed abortion after fresh/frozen-thawed single blastocyst transfer with IVF/ICSI treatment.

Objective:Analyzing the influence of morphological evaluation parameters of blastocysts, including days of blastocyst development [day 5 (D5) and day 6 (D6)], degree of blastocyst expansion (4, 5, 6), inner cell mass and trophectoderm grade, on the occurrence of chromosomal karyotype abnormalities of chorionic villi in missed abortion after in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment and fresh/frozen-thawed single blastocyst transfer. Methods:The clinical data of patients with missed abortion after IVF/ICSI treatment and fresh/frozen-thawed single blastocyst transfer from February 2015 to February 2023 in the Reproductive Center of the Third Affiliated Hospital of Zhengzhou University were included. Using a case-control study, the data were divided into two groups according to the detection results of chromosomal copy number variations (CNVs) in chorionic villi of missed abortion abnormal karyotype group ( n=139) and normal karyotype group ( n=82). The baseline data between the two groups were compared. Univariate logistic regression was used to investigate the effect of blastocyst morphological rating parameters on the occurrence of chromosomal karyotype abnormalities of chorionic villi in aborted tissues, and multivariate logistic regression was also used to adjust confounding factors. Results:Male age [(34.12±6.49) years], sperm morphology rate [5.00 (4.00,6.00)%] and female age [33.00 (30.00, 37.00) years] in abnormal karyotype group were higher than those in the normal karyotype group [(32.38±4.69) years, 4.00 (2.00,5.00)% and 31.50 (29.00,34.00) years], and the differences were statistically significant ( P=0.022, P=0.020, P=0.009). Univariate and multivariate logistic regression analyses showed that days of blastocyst development, degree of blastocyst expansion, inner cell mass and trophectoderm grade did not increase the risk of chromosomal karyotype abnormalities of chorionic villi (all P>0.05). Conclusion:There is no significant correlation between blastocyst morphological evaluation parameters and chromosomal karyotype abnormalities in chorionic villi of missed abortion after fresh/frozen-thawed single blastocyst transfer with IVF/ICSI treatment.

Objective:To compare perinatal outcomes of singleton live births between human assisted reproductive technology (ART) and spontaneously conceived (SC).Methods:This study was a retrospective cohort study, collecting data on patients who delivered and obtained singleton live birth in the Obstetrics Department of the Third Affiliated Hospital of Zhengzhou University between 2008 and 2019. A total of 1 727 ART patients were included in this study, and 5 181 SC patients who delivered during the same day were matched at a ratio of 1∶3. After matching according to delivery time, the baseline data of the two groups were matched using 1∶1 propensity score matching (PSM), and finally 1 439 patients were included in the ART and SC groups, respectively. The primary outcome measure was the healthy baby rate, and the secondary outcome measures were perinatal outcomes such as the incidences of hypertensive disorders of pregnancy, gestational diabetes and preterm delivery rate.Results:After PSM, healthy baby rate was lower in the ART group compared with the SC group [77.28% (1 112/1 439) vs. 70.67% (1 017/1 439), P<0.001]. Pregnancy complications, including the incidence of gestational diabetes, intrahepatic cholestasis syndrome during pregnancy, abnormal thyroid function during pregnancy, oligohydramnios, placenta previa, cesarean delivery, and placental efficiency, were statistically different between the two groups (all P<0.05). The neonatal outcomes, including gestational age, preterm delivery rate, very preterm delivery rate, incidence of small for gestation age and neonatal intensive care unit admission rate were statistically different between the two groups (all P<0.05). The results of multivariate logistic regression analysis showed that ART and pregnancy complications were risk factors for healthy baby ( OR=0.81, 95% CI:0.67-0.97, P=0.020), however, placental efficiency was a protective factor for healthy baby ( OR=1.73, 95% CI:1.59-1.88, P<0.001). Conclusion:Perinatal outcomes were safer in the SC group than in the ART group.

Objective:To compare perinatal outcomes of singleton live births between human assisted reproductive technology (ART) and spontaneously conceived (SC).Methods:This study was a retrospective cohort study, collecting data on patients who delivered and obtained singleton live birth in the Obstetrics Department of the Third Affiliated Hospital of Zhengzhou University between 2008 and 2019. A total of 1 727 ART patients were included in this study, and 5 181 SC patients who delivered during the same day were matched at a ratio of 1∶3. After matching according to delivery time, the baseline data of the two groups were matched using 1∶1 propensity score matching (PSM), and finally 1 439 patients were included in the ART and SC groups, respectively. The primary outcome measure was the healthy baby rate, and the secondary outcome measures were perinatal outcomes such as the incidences of hypertensive disorders of pregnancy, gestational diabetes and preterm delivery rate.Results:After PSM, healthy baby rate was lower in the ART group compared with the SC group [77.28% (1 112/1 439) vs. 70.67% (1 017/1 439), P<0.001]. Pregnancy complications, including the incidence of gestational diabetes, intrahepatic cholestasis syndrome during pregnancy, abnormal thyroid function during pregnancy, oligohydramnios, placenta previa, cesarean delivery, and placental efficiency, were statistically different between the two groups (all P<0.05). The neonatal outcomes, including gestational age, preterm delivery rate, very preterm delivery rate, incidence of small for gestation age and neonatal intensive care unit admission rate were statistically different between the two groups (all P<0.05). The results of multivariate logistic regression analysis showed that ART and pregnancy complications were risk factors for healthy baby ( OR=0.81, 95% CI:0.67-0.97, P=0.020), however, placental efficiency was a protective factor for healthy baby ( OR=1.73, 95% CI:1.59-1.88, P<0.001). Conclusion:Perinatal outcomes were safer in the SC group than in the ART group.

To investigate the therapeutical effect of the chitosan (CS) nana-paritclessingle administration of Bla g 7 polypeptide - CS nanoparticles used as a BLa g7 polypeptide antigen in the sensitized mice and to explore its immune mechanism, the polypeptide Bla g 7 was enclosed into CS to develop the Bla g 7 polypeptide entrapped CS nano-particles. In the present experiment, 25 BALB/c mice were divided randomly into the Bla g 7 polypeptide treated group(group A , n= 5) , Bla g 7 polypeptide plus CS treated group(group B , n= 5) , CS=control group (group C , n= 5),model group (group D , n= 5) and negative control group (group E, n= 5), After sensitization by intraperitoneal route and challenged by intranasal instillation with crude extracts of German cockroach , the inflammatory changes in the mouse lung tissues were observed after the lung tissues were fixed and stained with haematoxylin and eosin(H&E). The total cell number and the cellular composition of bronchoalveolar lavage fluid (BALF) were detected; and the changes of the mouse airway hyper-reactivity were determined by the whole body plethysmograohy pre-and post-treatments. In these ways, the Bla g7 peptide CS nano-particel vaccine was successfully developed. It was found that the pathological changes in mouse lungs in group D were not so prominent in comparison with those of group A of mice sensitized with crude extract of German cockroach. in which the development of eosinophil infiltration in the airway of mice in D group could be demonstrated. The lung inflammatory reactions and the mucus secretion in lungs of D group were significantly alleviated than those of the B group. but there was no therapeutical effect for the mice fed with the isodoses of Bla g 7 polypeptide or CS. It was also shown that the airway hyper-reactivity of mice was depressed after treatment (P<0.05). It is evident that CS nano-particles show definite therapeutical effect and may serve as a powerful vehicle to improve the tolerance effect of the Bla g 7 polypeptide-CS nanoparticle vaccine, and a single administration of Bla g 7 polypeptide-CS nanoparticle vaccine may hold promise as a new strategy to desensitize the Bla g 7 sensitized disease.